<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340326</url>
  </required_header>
  <id_info>
    <org_study_id>Donga 419</org_study_id>
    <nct_id>NCT01340326</nct_id>
  </id_info>
  <brief_title>The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling</brief_title>
  <acronym>VALID</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin-converting enzyme inhibitors and angiotensin-receptor blocker valsartan
      ameliorate ventricular remodeling after myocardial infarction (MI). Although the amount of
      those drugs used in previous clinical trials, therefore recommended in practical guidelines
      is maximum clinical dose, it has not been clearly demonstrated whether the recommended dose
      is more efficacious compared to lower dose commonly used in clinical practice. In addition,
      the impact of genetic polymorphism in neurohormonal system on the pharmacological effect has
      not been explored in the setting of post-MI remodeling.

      Therefore, the investigators evaluate whether submaximal dose, which are lower than those in
      major pivotal trials but typically used in clinical practice, can offer similar benefit in
      post-MI ventricular remodeling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 1116 patients with left ventricular (LV) dysfunction following the first episode
      of acute ST-elevation MI are to be enrolled and randomized to maximal tolerable dose (up to
      320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2:1 ratio.
      Echocardiographic analysis for quantifying post-MI ventricular remodeling and genotyping of
      blood samples are conducted in central core laboratory. Clinical assessment and laboratory
      test are performed at fixed times, and genetic polymorphisms of the patients are tested at
      the time of admission.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the left ventricular volume index from baseline to follow-up</measure>
    <time_frame>at 24hrs, 1month, and 12months after myocardial infarction</time_frame>
    <description>We measured a left ventriular volume index by echocardiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular volume index</measure>
    <time_frame>at 12months after myocardial infarction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical events</measure>
    <time_frame>during 12 months follow up</time_frame>
    <description>Clinical events were defined as all cause death and hospitalization due to cardiovascular problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical events</measure>
    <time_frame>at 12 months after myocardial infarction</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Valsartan,high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose group (valsartan up to 320 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan, usual dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>usual dose group (valsartan 80 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose of valsartan</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Valsartan,high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual dose of valsartan</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Valsartan, usual dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both gender

          -  Age &gt; 18

          -  First episode of acute ST-elevation MI

          -  An echocardiographic left ventricular ejection fraction less than 50 %

          -  Patients who provide written informed consent

        Exclusion Criteria:

          -  Contraindications for use of angiotensin receptor blockers (ARBs)(hypersensitivity,
             pregnancy, bilateral renal artery stenosis)

          -  Urgent need for revascularization procedure

          -  Severe heart failure (need for intravenous inotropic support)

          -  Persistent (&gt; 1 hour) severe hypotension (systolic blood pressure &lt; 90 mmHg)

          -  Refractory or potentially lethal arrhythmias

          -  Hemodynamically significant right ventricular infarction

          -  Primary valvular diseases

          -  Congenital heart disease

          -  Idiopathic hypertrophic cardiomyopathy

          -  Concomitant inflammatory cardiopathy

          -  Significant hepatic dysfunction

          -  Significant renal dysfunction

          -  Anemia (hemoglobin &lt; 10 mg/mL)

          -  Psychiatric disorders, alcohol or durg abuse

          -  Any concomitant disease that might interfere with drug evaluation (especially if life
             expectancy is less than 1 year)

          -  Participation in any other pharmacological study within 2 months

          -  Refusal or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal Medicine,Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Kyungil Park</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Post myocardial infarction ventricular remodeling</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

